Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Healthcare Medicaid topic
No spam. Unsubscribe anytime.
Committee Hears Hours of Testimony on Proposal to Require Medicaid Coverage for GLP‑1 Drugs
Summary
A lengthy committee hearing on Senate Bill 455 drew patients, clinicians and the Department of Health and Human Services to debate whether New Hampshire Medicaid should be required to cover GLP‑1 medications for obesity and related conditions; proponents cited clinical benefits and downstream savings while DHHS warned of large near‑term fiscal costs.
Senators and witnesses spent several hours debating Senate Bill 455, which would direct the New Hampshire Department of Health and Human Services to provide coverage for GLP‑1 medications under the state Medicaid plan when medically necessary. Senator Sue Apprentice, who introduced the measure, said the drugs are “clinically proven to reduce body weight by 10 to 20%” and argued that coverage could prevent costly complications such as amputation and dialysis.
The bill’s supporters included physicians, diabetes educators and patient advocates who described dramatic clinical results and urged access for low‑income residents. Hope Damon, a retired dietician and state representative testifying in support, told the committee that GLP‑1s are “far and away the most impactful” therapies for obesity and diabetes she has encountered in a 43‑year career.
Opponents included the New Hampshire Department of Health and Human Services, which recommended against the measure on fiscal grounds. Dr. Jonathan Ballard, the department’s chief medical officer, said Medicaid already covers GLP‑1 medications for many of the conditions listed in the bill but that a statutory mandate would create an “unfunded mandate” requiring the state to pay initially before a future appropriation. He told the committee the department’s estimate showed roughly $8.5 million in costs in fiscal 2027 and larger sums in later years, and said the department does not have the money in current biennial budgets to absorb that increase.
Several lawmakers pressed both sides on two related points: whether rising manufacturer prices would fall quickly enough to create long‑term savings and whether eligibility criteria in the bill — including a body‑mass index threshold and medical necessity language — were appropriately targeted. Senator Apprentice acknowledged the fiscal uncertainties and said her approach was to “get this into a place where it’s covered in statute” so it can be implemented if and when costs become sustainable.
The hearing produced detailed technical questions but no committee action during the session. Supporters asked the panel to consider the program as a prevention‑focused investment; the department urged more study, updated fiscal notes and a phased approach tied to available funding. The public record for the hearing includes extensive testimony from clinicians, advocacy groups and patients that the committee may weigh as it drafts next steps.
